NVSEF - Novartis AG
NEXT EARNINGS:
Apr 28, 2026
EPS Est: $2.11
|
Rev Est: $13.6B
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
Market Cap:
316.75B
Volume:
3,233
Avg Volume:
74,500
52 Week Range:
97.3-170.2
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.46
Last Dividend:
$3.98
Exchange:
OTC
Country:
CH
Employees:
75,883
IPO Date:
2010-04-26
EPS (TTM):
7.56
P/E Ratio:
18.27
Revenue (TTM):
57.13B
Total Assets:
115.49B
Total Debt:
37.01B
Cash & Equiv:
11.43B
Rev Growth (5Y):
2.7%
EPS Growth (5Y):
15.0%
FCF Growth (5Y):
10.7%
ROCE:
20.8%
Debt/Equity:
0.80
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-04 | $1.26 | $1.99 | -36.7% | $13.4B | $13.3B | +0.9% |
| 2025-07-17 | $2.06 | $2.35 | -12.3% | $14.8B | $13.7B | +8.5% |
| 2025-04-29 | $1.85 | $2.11 | -12.3% | $13.6B | $13.9B | -2.0% |
| 2025-01-31 | $1.41 | $1.80 | -21.7% | $13.6B | $12.8B | +5.6% |
| 2024-10-29 | $1.57 | $1.94 | -19.1% | $13.2B | $12.8B | +3.0% |
| 2024-07-18 | $1.59 | $1.85 | -14.1% | $12.6B | $12.5B | +1.1% |
| 2024-04-23 | $1.31 | $1.68 | -22.0% | $11.5B | $11.4B | +0.2% |
| 2024-03-05 | $4.11 | $1.65 | +149.1% | $11.8B | $11.9B | -0.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.13B | 51.72B | 46.66B | 51.83B | 52.88B | 49.90B | 48.68B | 53.17B | 50.13B | 49.44B | 50.39B | 53.63B |
| Net Income | 14.65B | 11.94B | 14.85B | 6.96B | 24.02B | 8.07B | 11.73B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B |
| EPS | 7.56 | 5.92 | 7.63 | 3.29 | 10.73 | 3.76 | 3.15 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 |
| Total Assets | 115.49B | 102.25B | 99.94B | 117.45B | 131.79B | 132.06B | 118.37B | 145.56B | 133.08B | 130.12B | 131.56B | 125.39B |
| Total Debt | 37.01B | 31.26B | 26.35B | 27.96B | 31.09B | 38.05B | 29.33B | 32.09B | 28.43B | 23.80B | 21.93B | 20.41B |
| Cash & Equivalents | 11.43B | 11.46B | 13.39B | 7.52B | 12.41B | 9.66B | 11.11B | 13.27B | 8.86B | 7.01B | 4.67B | 13.02B |
| Operating Cash Flow | 20.05B | 17.62B | 14.46B | 14.24B | 15.07B | 13.65B | 13.62B | 14.27B | 12.62B | 11.47B | 11.90B | 13.90B |
| Free Cash Flow | 18.43B | 13.80B | 11.71B | 11.56B | 12.10B | 11.06B | 11.37B | 10.92B | 9.88B | 8.60B | 8.05B | 10.19B |
| FCF per Share | 9.51 | 6.84 | 5.64 | 5.30 | 5.40 | 4.86 | 4.96 | 4.71 | 4.21 | 3.61 | 3.35 | 4.20 |
| Book Value | 46.10B | 44.05B | 46.67B | 59.34B | 67.66B | 56.60B | 55.47B | 78.61B | 74.17B | 74.83B | 77.05B | 70.77B |
| Cash & ST Investments | 11.58B | 13.35B | 14.07B | 18.93B | 28.33B | 11.56B | 11.45B | 15.96B | 9.48B | 7.78B | 5.45B | 13.86B |
| ROC Equity | 0.32 | 0.27 | 0.32 | 0.12 | 0.36 | 0.14 | 0.21 | 0.16 | 0.10 | 0.09 | 0.23 | 0.14 |